Comprehensive Pan-Cancer Bioinformatics Analysis Identifies DHX58 as a Promising Therapeutic Target and Prognostic Biomarker Across Multiple Tumor Types.

Authors

Hussam S Aziz, Ayoob Radhi Al-Zaalan

Published in

Asian Pacific journal of cancer prevention : APJCP. Volume 27. Issue 6. Pages 2117-2127. Jun 01, 2026. Epub Jun 01, 2026.

Abstract

DExH-box helicase 58 (DHX58/LGP2) is an innate immune regulator with a previously uncharacterized role in oncology. This study evaluates the multifaceted role of the DHX58 gene, examining its pan-cancer expression, prognostic value, and therapeutic potential across various tumor types through an extensive pan-cancer bioinformatics analysis.
We conducted a bioinformatics analysis of DHX58 using TCGA and GTEx data from four platforms: GEPIA2, TIMER 2.0, UALCAN, and starBase. We assessed differential expression, prognostic significance and survival outcomes, drug sensitivity, functional enrichment, genomic alterations, protein-protein interactions, and DNA methylation across 32 cancer types.
Our findings revealed that the differential expression of the DHX58 gene across numerous cancers was context-dependent, with consistent downregulation in lung squamous cell carcinoma and upregulation in head and neck squamous cell carcinoma. Low DHX58 expression correlated with poor survival in kidney chromophobe renal cell carcinoma, sarcoma, and skin melanoma, but with favorable outcomes in other cancers, such as colon adenocarcinoma. Notably, low DHX58 expression was associated with increased sensitivity to birinapant and saracatinib. Genomic alterations were infrequent, and methylation patterns were largely unchanged. Functional enrichment analysis emphasized DHX58's established role in innate immunity and antiviral responses, with its co-expressed genes implicated in viral defense pathways. Genomic profiling identified various alterations, including mutations and copy number variations, contributing to DHX58 dysregulation. Protein-protein interaction mapping solidified its central role in immune signaling, while DNA methylation analysis highlighted epigenetic regulation as another layer of control.
Our pan-cancer analysis reveals that DHX58 has context-specific prognostic and predictive roles. While discrepancies between platforms exist, DHX58 emerges as a potential biomarker in specific cancers, particularly in the context of therapies involving agents like birinapant. These findings warrant further mechanistic and clinical investigation.

PMID:
42345158
Bibliographic data and abstract were imported from PubMed on 25 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.